Search research articles
Contact Us
Filters
Showing results (21-30 of 36) with videos related to
Page
of 4
Sort By:
Scientific Reports
|
July 2, 2025
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
Shogo Adomi, Kazuko Sakai, Yurie Kura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
Takuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Anticancer Research
|
May 27, 2026
Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma
Yuya Oishi, Yuto Matsushita, Shinya Watanabe, et al.
Anticancer Research
|
August 1, 2025
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy
Koichi Sugimoto, Takafumi Minami, Shingo Toyoda, et al.
Cancer Immunology, Immunotherapy : CII
|
February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Japanese Journal of Clinical Oncology
|
August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy
Shingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
Japanese Journal of Clinical Oncology
|
May 17, 2026
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy
Shinya Watanabe, Yuto Matsushita, Yuya Oishi, et al.
World Journal of Urology
|
September 26, 2024
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy
Kazutoshi Fujita, Yuto Matsushita, Shingo Toyoda, et al.
International Journal of Clinical Oncology
|
September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab
Keiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Cancer Science
|
December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men
Saizo Fujimoto, Koji Hatano, Eri Banno, et al.
Page
of 4
Search research articles
Search
Showing results (21-30 of 36) with videos related to
Sort By:
Page
of 4
Scientific Reports
|
July 2, 2025
Comparison of genetic mutations in bladder cancers that arose following radiotherapy for prostate cancer with those in primary bladder cancers
Shogo Adomi, Kazuko Sakai, Yurie Kura, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association
|
August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative Study
Takuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Anticancer Research
|
May 27, 2026
Development of a Prognostic Model for Patients Aged ≤65 Years With Metastatic Renal Cell Carcinoma
Yuya Oishi, Yuto Matsushita, Shinya Watanabe, et al.
Anticancer Research
|
August 1, 2025
Rash and Endocrine Disorders Predict Improved Survival in Metastatic Renal Cell Carcinoma Treated With Immunotherapy
Koichi Sugimoto, Takafumi Minami, Shingo Toyoda, et al.
Cancer Immunology, Immunotherapy : CII
|
February 25, 2026
A real-world comparison of nivolumab plus cabozantinib and pembrolizumab plus lenvatinib focusing on safety outcomes in metastatic renal cell carcinoma: results from the JK-FOOT consortium
Takafumi Yanagisawa, Keiichiro Mori, Tatsushi Kawada, et al.
Japanese Journal of Clinical Oncology
|
August 23, 2024
Clinical outcomes and prognostic factors in metastatic nonclear cell renal cell carcinoma treated with immuno-oncology combination therapy
Shingo Toyoda, Wataru Fukuokaya, Keiichiro Mori, et al.
Japanese Journal of Clinical Oncology
|
May 17, 2026
Development of a prognostic model for elderly patients with metastatic clear cell renal cell carcinoma treated with first-line immuno-oncology combination therapy
Shinya Watanabe, Yuto Matsushita, Yuya Oishi, et al.
World Journal of Urology
|
September 26, 2024
The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy
Kazutoshi Fujita, Yuto Matsushita, Shingo Toyoda, et al.
International Journal of Clinical Oncology
|
September 5, 2025
Predictors of early progressive disease and antitumor effects by metastatic site in renal cell carcinoma treated with ipilimumab plus nivolumab
Keiichiro Mori, Takafumi Yanagisawa, Tatsushi Kawada, et al.
Cancer Science
|
December 4, 2024
Comparative analysis of gut microbiota in hormone-sensitive and castration-resistant prostate cancer in Japanese men
Saizo Fujimoto, Koji Hatano, Eri Banno, et al.
Page
of 4